A Phase 1 Study of NEU-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect in Healthy Volunteers
Latest Information Update: 04 Apr 2025
At a glance
- Drugs NEU 627 (Primary)
- Indications Multiple sclerosis; Neurological disorders
- Focus Adverse reactions
- Sponsors Neuron23
- 04 Apr 2025 New trial record